Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. - Griffiths, Christopher E. M.; Papp, Kim A.; Song, Michael; Miller, Megan; You, Yin; Shen, Yaung-Kaung; Han, Chenglong; Blauvelt, Andrew (Journal of Dermatological Treatment, 2022)